How is adult ADHD diagnosed in Australia?

Diagnosis requires comprehensive clinical assessment — not a quick questionnaire alone. A clinician takes a detailed history of current symptoms (inattention, hyperactivity-impulsivity, functional impact) and confirms onset before age 12, often with family or school-record collateral. The ASRS screen (6-item Part A) and structured DIVA-5 interview support the process. Investigations rule out mimics: thyroid function, B12, iron studies, and a sleep study if obstructive sleep apnoea is suspected. GPs typically initiate the workup and refer to a psychiatrist or paediatrician with adult ADHD expertise for diagnosis confirmation and medication initiation.

Do I need a specialist to get ADHD medication in Australia?

Usually yes, initially. All first- and second-line ADHD medications are PBS Authority Required, and stimulants are Schedule 8 controlled drugs with state-based authority requirements. In most states, a specialist — psychiatrist or authorised paediatrician — must initiate treatment. Once stable, many states allow GP shared care for ongoing prescribing and monitoring. In areas where specialist access is very limited, some states have expanded GP prescribing pathways. The RACGP has advocated for broader GP prescribing rights nationally. Check your state's Department of Health guidelines, as rules vary.

What medications are used for adult ADHD in Australia?

Stimulants are first-line. Methylphenidate (Ritalin, Ritalin LA, Concerta) acts on dopamine and noradrenaline reuptake. Lisdexamfetamine (Vyvanse) is a pro-drug — converted after absorption — with reduced abuse potential and 10–14 hours of action. Dexamfetamine is a third stimulant option. All are PBS Authority Required Schedule 8 drugs. Non-stimulant options — atomoxetine (Strattera, selective noradrenaline reuptake inhibitor) and guanfacine ER (Intuniv, alpha-2 agonist) — suit those with cardiovascular contraindications, active substance use disorder, or stimulant intolerance. Atomoxetine takes 4–8 weeks to reach full effect.

Are there risks with stimulant medication?

Stimulants are among the most studied psychiatric medications with a well-characterised side-effect profile: appetite suppression, weight loss, insomnia, irritability, headache, and modest increases in blood pressure and heart rate. Cardiovascular assessment — including ECG if risk factors are present — is mandatory before starting. Stimulants are contraindicated in structural heart disease, severe uncontrolled hypertension, or recent myocardial infarction. There is a misuse and diversion risk, which is why lisdexamfetamine (a pro-drug) is often preferred over immediate-release amphetamines. Monitoring of blood pressure, weight, and mental state at every review visit helps catch problems early.

What helps beyond medication?

Quite a lot. CBT specifically adapted for adult ADHD — addressing organisation, time management, procrastination, and emotional regulation — has robust evidence and is accessible via Medicare-subsidised psychology through a Mental Health Care Plan. Regular aerobic exercise (20–40 minutes most days) acutely improves attention and executive function. Consistent sleep schedule and treating any underlying sleep apnoea reduce symptom burden. External structure — digital calendars, task lists, visual timers, body-doubling, and noise-cancelling headphones — offloads executive demand from the brain. Psychoeducation for partners and family reduces relationship strain from misunderstood ADHD behaviours.

Can ADHD be missed in women?

Yes — historically it frequently was. Women are more likely to present with the predominantly inattentive subtype: appearing disorganised and underachieving without the disruptive hyperactive behaviour that prompted earlier recognition in boys. Compensatory masking — working very hard to appear organised — can delay diagnosis until functional demands exceed capacity. Hormonal fluctuations across the menstrual cycle and perimenopause affect symptom severity via oestrogen's influence on dopamine pathways. Women diagnosed in adulthood often report years of misdiagnosis as anxiety or depression. The AADPA 2022 guideline specifically addresses gender disparities in recognition and under-diagnosis.

Adult attention deficit hyperactivity disorder (ADHD)

Adult ADHD: diagnosis and management in Australian general practice

By Dr HB Lo, FACRRM Reviewed 25 May 2026 11 min read

Adult ADHD is a neurodevelopmental condition affecting ~3–5% of Australian adults, with pervasive inattention and/or hyperactivity-impulsivity present before age 12 and impairing function across work, home, and relationships.

The AADPA 2022 guideline (RANZCP-endorsed) recommends specialist-initiated stimulant therapy — methylphenidate, lisdexamfetamine, or dexamfetamine — as first-line. Non-stimulant options (atomoxetine, guanfacine) suit those with contraindications to stimulants.

CBT for adult ADHD, structured routines, sleep optimisation, and regular aerobic exercise are important non-pharmacological supports alongside pharmacotherapy.

What adult ADHD is

Adult ADHD is a neurodevelopmental disorder — a brain-based difference in dopamine and noradrenaline signalling affecting prefrontal cortical function — characterised by pervasive inattention and/or hyperactivity-impulsivity that was present before age 12 and continues to cause meaningful impairment in adult life. It is neither a character flaw nor a childhood condition people outgrow: approximately 50–60% of children with ADHD carry the diagnosis into adulthood, producing an estimated adult prevalence of 3–5% in Australia.

In Australian general practice, adult ADHD is one of the most under-diagnosed and under-treated chronic conditions. Many adults — particularly women — were never identified in childhood. The resulting diagnostic gap carries real consequences: ADHD untreated in adulthood is associated with lower educational attainment, underemployment, relationship instability, financial difficulty, and approximately three times the motor vehicle accident rate of neurotypical peers. Comorbid anxiety and depression affect roughly half of people with ADHD; substance use disorder affects around a quarter.

The nationally authoritative reference is the AADPA 2022 Australian ADHD guideline — developed under NHMRC auspices and endorsed by the RANZCP in April 2024, superseding earlier RANZCP guidance. Alongside eTG Psychotropic, AMH monographs, and the Australian Prescriber pharmacotherapy article, this guideline forms the clinical backbone for Australian practice.

This article explains how adult ADHD is assessed, what treatment involves, and how the Australian healthcare system — PBS-listed medications, Medicare pathways, and state stimulant authority frameworks — supports management.

A. Core clinical — the AU general-practice framework

DSM-5 criteria for adults

DSM-5 adult criteria require:

≥5 inattention symptoms AND/OR ≥5 hyperactivity-impulsivity symptoms (reduced from ≥6 in childhood criteria, reflecting maturation and compensatory mechanisms)
Symptoms present before age 12 — often recalled poorly; collateral from parents, siblings, or school records is helpful
Symptoms present across ≥2 settings — work, home, social, financial, driving
Significant functional impairment in those settings
Not better explained by another condition

Inattention symptoms include: sustained attention difficulty, careless mistakes, poor organisation, forgetfulness, losing things, avoidance of mentally demanding tasks, and distractibility. Hyperactivity-impulsivity symptoms include: restlessness, difficulty remaining seated, excessive talking, blurting out answers, difficulty awaiting turns, and interrupting.

Subtypes: predominantly inattentive (more common in women, frequently missed); predominantly hyperactive-impulsive (less common in adults); combined (most prevalent overall).

Who develops adult ADHD

Adult sex ratio is roughly 1:1 — a significant shift from childhood (males 2–3:1), reflecting historical under-diagnosis in girls and women. The AADPA 2022 guideline specifically addresses this disparity. Genetics are strongly implicated: first-degree relatives of people with ADHD have a four- to fivefold elevated risk. Autism spectrum conditions frequently co-occur — estimated 30–50% overlap — adding diagnostic complexity.

Assessment in general practice

History:

Current symptoms: what specific inattention or hyperactivity-impulsivity behaviours occur, and how they impair work, study, relationships, finances, and driving
Childhood history: symptoms before age 12; corroborative collateral from parents or school records helps where recall is poor
Comorbidities: anxiety, depression, bipolar disorder, autism, learning difficulties, substance use, sleep disorders
Cardiac history: structural heart disease, family history of sudden cardiac death, arrhythmia
Substance use: cannabis, alcohol, stimulant misuse — comorbidity and diversion risk
Mental state: screen for mania/hypomania (bipolar can mimic or co-occur with ADHD and destabilises on stimulants)

Validated screening tools recommended by AADPA 2022:

ASRS (Adult ADHD Self-Report Scale) — 6-item Part A screen; ≥4 positive responses = strong likelihood of ADHD; free, validated, widely used
DIVA-5 — structured diagnostic interview for adult ADHD; comprehensive; specialist-preferred
WURS (Wender Utah Rating Scale) — retrospective childhood recall
CAARS (Conners Adult ADHD Rating Scales) — quantified symptom severity

Examination: mental state including mania/psychosis screen; vitals (blood pressure, heart rate, weight); cardiovascular auscultation; sleep history and obstructive sleep apnoea screen.

Investigations:

Bloods: FBC, UEC, LFT, TSH, B12, vitamin D, iron studies, glucose/HbA1c, lipids — to exclude mimics and establish a baseline before stimulants
ECG before stimulant initiation in those with cardiovascular risk factors; MBS item 11707
Sleep study if obstructive sleep apnoea features are prominent

Mimics to exclude: anxiety disorders, major depressive disorder, bipolar disorder, obstructive sleep apnoea, hypothyroidism, B12 deficiency, iron deficiency anaemia, substance use, traumatic brain injury, and early neurodegenerative disease. Many of these conditions worsen inattention and must be managed regardless of ADHD status.

Medicare pathways:

Standard consultations: items 3/23/36/44
Mental Health Care Plan: items 2700/2701/2715/2717; review 2712 — for comorbid anxiety or depression
Better Access Initiative: up to 10 subsidised psychology sessions/year for CBT for adult ADHD
ECG item 11707; pathology bulk-billed at most practices
GPMP/TCA items 965/967 for chronic ADHD with significant comorbidity burden

B. Pharmacotherapy — what the evidence says

Stimulants: first-line

The AADPA 2022 guideline and Australian Prescriber pharmacotherapy review both position stimulants as first-line pharmacotherapy for adult ADHD. Effect sizes (Cohen’s d approximately 0.8–1.0) are among the largest in psychopharmacology.

Methylphenidate (per AADPA 2022 and AMH):

Immediate-release (Ritalin 5–10 mg, two to three times daily) or modified-release (Ritalin LA, Concerta) once daily — doses per AMH
Duration of effect: IR 3–5 hours; Concerta 8–12 hours
Start at the lower end of the dose range and titrate fortnightly to response and tolerability

Lisdexamfetamine (Vyvanse) (per AADPA 2022 and AMH):

Pro-drug converted to dexamfetamine after absorption — substantially reduced abuse and diversion potential; doses per AMH
30 mg each morning; titrate to 50–70 mg; duration 10–14 hours
Preferred by many clinicians when diversion risk or substance use history is a concern

Dexamfetamine (per AADPA 2022 and AMH):

5 mg two to three times daily; useful where methylphenidate is poorly tolerated
Shorter acting; more variable dosing

All three are PBS Authority Required, Schedule 8, and subject to state-based controlled drug regulations.

Cardiovascular monitoring: stimulants produce modest increases in blood pressure and heart rate. Absolute contraindications include structural heart disease, symptomatic arrhythmia, severe uncontrolled hypertension, and recent myocardial infarction. Per eTG Psychotropic, pre-prescribing cardiovascular assessment — including ECG in those with risk factors — is mandatory. Blood pressure and heart rate should be checked at every review.

Side effects to monitor: appetite suppression (typically peak mid-morning), weight loss, insomnia, irritability, anxiety, headache, dry mouth, and mood lability. If insomnia is problematic, consider adjusting the timing or switching from modified-release to immediate-release to reduce duration of action.

Non-stimulant options: second-line

When stimulants are contraindicated or not tolerated, AMH monographs and eTG Psychotropic support two PBS-listed alternatives:

Atomoxetine (Strattera):

Selective noradrenaline reuptake inhibitor; not a controlled drug; no abuse potential — the preferred option in active substance use disorder
40 mg increasing to 80–100 mg daily (weight-based; per AMH); full therapeutic effect at 4–8 weeks
Also useful in comorbid anxiety or cardiovascular contraindication to stimulants
PBS Authority Required

Guanfacine ER (Intuniv):

Alpha-2 adrenoceptor agonist; 1–4 mg daily (per AMH); sedating at higher doses
Useful as adjunct or alternative, particularly in young adults with prominent emotional dysregulation
PBS Authority Required

Psychological treatment

Psychological intervention is a core management component, not an optional extra. CBT specifically adapted for adult ADHD targets the executive-function deficits that medication alone does not fully address: organisation, planning, time management, prioritisation, emotional regulation, and procrastination patterns. Meta-analyses confirm significant additive benefit over medication alone, with moderate effect sizes for functional outcomes. Better Access psychology sessions (up to 10 per year via Mental Health Care Plan) are the primary AU access pathway. Psychoeducation for patients — and for partners and family — is an essential part of every management plan.

C. Non-pharmacological strategies and lifestyle

Managing ADHD well involves a set of evidence-informed, practical strategies that complement pharmacotherapy.

Sleep optimisation: sleep deprivation markedly worsens inattention and impulse control. Adults with ADHD have elevated rates of comorbid insomnia, delayed sleep phase disorder, and obstructive sleep apnoea. Treating sleep apnoea (CPAP if indicated), applying CBT-I sleep restriction and stimulus control principles, and protecting consistent sleep timing all yield meaningful ADHD symptom improvement. Sleep Health Foundation resources provide AU-specific patient-oriented guidance.

Aerobic exercise: robust evidence supports a causal effect of moderate-intensity aerobic exercise on attention, working memory, and executive function in ADHD. Twenty to forty minutes of sustained effort — brisk walking, cycling, swimming, or running — produces acute benefits; twice-weekly minimum, daily preferred. This is not a substitute for treatment but is a meaningful and accessible supplement.

External scaffolding and structured routine: the brain with ADHD functions better when decisions are made in advance and the environment reduces executive demand. Practical strategies: digital calendar with timed alerts, time-blocking work tasks, written task lists, visual timers (Pomodoro technique), “body-doubling” (working alongside another person for accountability), noise-cancelling headphones, and a dedicated workspace free of non-work notifications.

Nutrition: a Mediterranean diet pattern — high in vegetables, fruit, wholegrains, legumes, olive oil, and fish — shows modest favourable associations in ADHD observational data. Omega-3 supplementation (fish oil) has meta-analytic support for a small additive symptom benefit as an adjunct to standard care. Regular meals prevent attention lapses driven by hunger.

Substance moderation: cannabis worsens attentional function chronically, despite a perceived acute calming effect. Alcohol fragments sleep architecture and worsens impulse control. Open, non-judgmental conversations about substance use are an important part of ADHD management — untreated ADHD frequently drives self-medication patterns.

Psychoeducation and peer support: understanding that ADHD reflects a neurobiological difference in dopamine and noradrenaline regulation — rather than laziness or moral failure — reduces shame, improves treatment adherence, and supports constructive self-management. ADHD Australia and AADPA provide peer networks, lived-experience communities, and advocacy.

D. Australian operations

State-based stimulant prescribing

Stimulants for ADHD are Schedule 8 (S8) controlled drugs in Australia. State and territory health departments each maintain their own authority and permit frameworks, layered on top of PBS requirements:

NSW: NSW Health stimulant authority; specialist initiation typically required; GP prescribing permitted under specialist supervision
Victoria: Drugs and Poisons Regulations Group permit; specialist initiation; some GP-led pathways where specialist access is absent
Queensland: specialist initiation required; GP shared care formalised in some regions; RACGP has advocated for expanded GP prescribing authority
Western Australia: specialist initiation; GP shared care post-stabilisation
SA / Tasmania / NT / ACT: varied; each state/territory Department of Health publishes current rules

Practical implication: many adults seeking first diagnosis face waits of three to six months or longer for a private psychiatrist assessment in metropolitan areas; public ADHD services are limited. During the waitlist period, GPs can usefully: complete the clinical workup, initiate a Mental Health Care Plan for psychology support, manage comorbid anxiety or depression, and review lifestyle factors.

PBS-listed ADHD medications

Drug	Form	Schedule
Methylphenidate (Ritalin, Ritalin LA, Concerta)	IR + MR	S8
Dexamfetamine	IR	S8
Lisdexamfetamine (Vyvanse)	MR (pro-drug)	S8
Atomoxetine (Strattera)	Capsule	S4
Guanfacine ER (Intuniv)	Modified-release	S4

Current Authority criteria and PBS listings are verified at PBS Online. Prescribers should confirm current criteria before initiating Authority applications.

Follow-up cadence

Per eTG Psychotropic and AADPA 2022:

Titration phase: review every two to four weeks
Stable treatment: three-monthly GP reviews
Each review: blood pressure, heart rate, weight, mental state, sleep, appetite, substance use, side effects, and functional improvement
Annual: selective ECG, repeat bloods, comorbidity audit
Stimulant scripts: frequency per state regulations, typically monthly S8 prescriptions

E. Special populations

Women and late-diagnosed adults: hormonal fluctuations across the menstrual cycle and through perimenopause modulate symptom severity via oestrogen’s influence on dopamine signalling. Women may notice worsening in the premenstrual phase or at perimenopause — a recognised clinical pattern that may warrant dose adjustment. Women presenting with long-standing anxiety or depression that hasn’t fully responded to treatment warrant an ADHD screen.

Pregnancy: stimulants are generally avoided in pregnancy due to limited safety data and a potential teratogenic signal. Dexamfetamine has the most pregnancy data but risk-benefit decisions require specialist obstetric and psychiatric input. Behavioural management and psychological strategies are preferred where possible. Post-partum management is individualised based on breastfeeding intent and symptom severity.

Older adults: ADHD does not resolve with age, but is often masked by life structure. Cardiovascular comorbidity becomes more clinically relevant at older age — thorough cardiac assessment before any stimulant initiation. Cognitive assessment to distinguish ADHD from early neurodegenerative change is sometimes warranted; specialist neuropsychological evaluation assists clarification.

Comorbid substance use disorder: ADHD and substance use disorder are strongly co-occurring conditions. Untreated ADHD is a significant driver of substance use (the self-medication hypothesis has substantial supporting evidence). Lisdexamfetamine — as a pro-drug with reduced abuse potential — is preferred over immediate-release stimulants in patients with substance use history. Atomoxetine provides a non-controlled drug option. Coordination with addiction services is essential.

Comorbid autism spectrum: ADHD and autism spectrum disorder co-occur in approximately 30–50% of autistic individuals. Diagnosis requires specialist expertise; stimulant response may differ from non-autistic individuals; management is highly individualised.

Aboriginal and Torres Strait Islander peoples: ADHD is under-recognised in Aboriginal and Torres Strait Islander communities, with trauma, systemic barriers, and cultural factors all affecting presentation and engagement with services. Culturally appropriate assessment pathways and community health worker involvement are important. The MBS item 715 health assessment provides a framework for comprehensive health checks that can incorporate ADHD screening.

When to escalate

Refer or seek specialist input when:

Diagnosis is uncertain and differentiation from anxiety, depression, bipolar disorder, autism, or learning disorder requires psychometric clarification
Active substance use disorder complicates stimulant initiation — addiction specialist involvement
Cardiovascular concern before stimulant initiation — cardiology assessment
Inadequate response to two adequately trialled stimulants at therapeutic doses — psychiatrist review of diagnosis and regimen
Comorbid bipolar disorder, psychosis, or eating disorder — joint psychiatric management
Active suicidal ideation — acute mental health services
Pregnancy — obstetric and psychiatric shared care
Stimulant-related cardiac event, severe psychiatric emergency, or substance crisis — emergency department

Crisis contacts: Lifeline 13 11 14 · Beyond Blue 1300 22 4636 · SANE Australia 1800 187 263.

What this article is and is not

This is general health information drawn from current Australian clinical guidelines — the AADPA 2022 ADHD guideline, Therapeutic Guidelines (eTG Psychotropic), Australian Medicines Handbook, RANZCP endorsement, and RACGP resources — alongside peer-reviewed pharmacotherapy evidence. It is not personal medical advice and does not create a doctor–patient relationship. Treatment decisions, including whether to pursue a formal assessment, which medications are appropriate, and how to manage comorbidities, are made collaboratively with your own GP and specialist clinicians.

For Australian consumer-friendly information: HealthDirect — ADHD · ADHD Australia · AADPA · Better Health Channel.

For acute mental-health crisis: Lifeline 13 11 14 · Beyond Blue 1300 22 4636.

Sources cited

Frequently asked questions

How is adult ADHD diagnosed in Australia?

Diagnosis requires comprehensive clinical assessment — not a quick questionnaire alone. A clinician takes a detailed history of current symptoms (inattention, hyperactivity-impulsivity, functional impact) and confirms onset before age 12, often with family or school-record collateral. The ASRS screen (6-item Part A) and structured DIVA-5 interview support the process. Investigations rule out mimics: thyroid function, B12, iron studies, and a sleep study if obstructive sleep apnoea is suspected. GPs typically initiate the workup and refer to a psychiatrist or paediatrician with adult ADHD expertise for diagnosis confirmation and medication initiation.
Do I need a specialist to get ADHD medication in Australia?

Usually yes, initially. All first- and second-line ADHD medications are PBS Authority Required, and stimulants are Schedule 8 controlled drugs with state-based authority requirements. In most states, a specialist — psychiatrist or authorised paediatrician — must initiate treatment. Once stable, many states allow GP shared care for ongoing prescribing and monitoring. In areas where specialist access is very limited, some states have expanded GP prescribing pathways. The RACGP has advocated for broader GP prescribing rights nationally. Check your state's Department of Health guidelines, as rules vary.
What medications are used for adult ADHD in Australia?

Stimulants are first-line. Methylphenidate (Ritalin, Ritalin LA, Concerta) acts on dopamine and noradrenaline reuptake. Lisdexamfetamine (Vyvanse) is a pro-drug — converted after absorption — with reduced abuse potential and 10–14 hours of action. Dexamfetamine is a third stimulant option. All are PBS Authority Required Schedule 8 drugs. Non-stimulant options — atomoxetine (Strattera, selective noradrenaline reuptake inhibitor) and guanfacine ER (Intuniv, alpha-2 agonist) — suit those with cardiovascular contraindications, active substance use disorder, or stimulant intolerance. Atomoxetine takes 4–8 weeks to reach full effect.
Are there risks with stimulant medication?

Stimulants are among the most studied psychiatric medications with a well-characterised side-effect profile: appetite suppression, weight loss, insomnia, irritability, headache, and modest increases in blood pressure and heart rate. Cardiovascular assessment — including ECG if risk factors are present — is mandatory before starting. Stimulants are contraindicated in structural heart disease, severe uncontrolled hypertension, or recent myocardial infarction. There is a misuse and diversion risk, which is why lisdexamfetamine (a pro-drug) is often preferred over immediate-release amphetamines. Monitoring of blood pressure, weight, and mental state at every review visit helps catch problems early.
What helps beyond medication?

Quite a lot. CBT specifically adapted for adult ADHD — addressing organisation, time management, procrastination, and emotional regulation — has robust evidence and is accessible via Medicare-subsidised psychology through a Mental Health Care Plan. Regular aerobic exercise (20–40 minutes most days) acutely improves attention and executive function. Consistent sleep schedule and treating any underlying sleep apnoea reduce symptom burden. External structure — digital calendars, task lists, visual timers, body-doubling, and noise-cancelling headphones — offloads executive demand from the brain. Psychoeducation for partners and family reduces relationship strain from misunderstood ADHD behaviours.
Can ADHD be missed in women?

Yes — historically it frequently was. Women are more likely to present with the predominantly inattentive subtype: appearing disorganised and underachieving without the disruptive hyperactive behaviour that prompted earlier recognition in boys. Compensatory masking — working very hard to appear organised — can delay diagnosis until functional demands exceed capacity. Hormonal fluctuations across the menstrual cycle and perimenopause affect symptom severity via oestrogen's influence on dopamine pathways. Women diagnosed in adulthood often report years of misdiagnosis as anxiety or depression. The AADPA 2022 guideline specifically addresses gender disparities in recognition and under-diagnosis.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.

T1 AU primary 13 sources